In Ohio, the Cleveland Clinic joined the Circulating Cell-free Genome Atlas, a national clinical trial that is looking for 7,000 cancer patients and 3,000 healthy patients in the U.S. Their goal is to analyze DNA and RNA in the blood and build a database that will help with detecting cancer early on when it is easier to cure. Researchers believe that using genome sequencing from blood samples could possibly replace x-rays for early cancer detection. Funded by a company in California, GRAIL, Inc., the project will be looking for molecule patterns in the blood for specific types of cancers.
Latest article
Jurassic couture: Partnership looks to use T-Rex DNA to create dino leather handbags
In the Netherlands, a consortium of companies is looking to grow material similar to that of T-Rex skin to create a truly unique leather...
Chick-fil-A’s lemon waste eyed for bioplastics
In California, waste from Chick-fil-A’s lemon juice supplier could one day be used to produce bioplastics.
Bay Center Foods, which provides all of the...
Greek Startup Coffeeco Raises 715K Euros
In Greece, Coffeeco Upgrade SA, a company converting coffee waste into products like makeup and bioplastics, has raised €715,000 in the first close of...